Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Paul-Peter Tak |
Contact Details
Address: 117 Kendrick Street, Suite 450 Needham, Massachusetts 02494 United States | |
| Phone | 617 916 5445 |
| Website | candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer and Director |
| Charles Schoch | Senior Vice President, Chief Financial Officer, Treasurer and Secretary |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical and Development Officer |
| Ileen B. Winick | Chief People Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Dr. William Nichols Garrett M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 8-K | Current Report |
| May 15, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |